2. Academic Validation
  3. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer

Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer

  • Eur J Med Chem. 2022 Aug 5:238:114470. doi: 10.1016/j.ejmech.2022.114470.
Sravani Pulya 1,  Tarun Patel 1,  Milan Paul 2,  Nilanjan Adhikari 3,  Suvankar Banerjee 3,  Ganesh Routholla 1,  Swati Biswas 2,  Tarun Jha 4,  Balaram Ghosh 5
Affiliations

Affiliations

  • 1 Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
  • 2 Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
  • 3 Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata, 700032, West Bengal, India.
  • 4 Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata, 700032, West Bengal, India. Electronic address: tjupharm@yahoo.com.
  • 5 Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad, 500078, India. Electronic address: balaram@hyderabad.bits-pilani.ac.in.
PMID: 35635949 DOI: 10.1016/j.ejmech.2022.114470
Abstract

A promising hydrazide based small molecule lead as a potent and selective histone deacetylase 3 (HDAC3) inhibitor has been developed from a small series of synthesized novel chemical entities. The lead compound (4e) displayed high HDAC3 inhibitory potency (IC50 = 15.41 nM) and a minimum of 18-fold selectivity over Other HDAC isoforms. It also exhibited potent cytotoxicity against several Cancer cell lines with minimal toxicity against normal cell lines tested. Compound 4e also enhanced acetylation levels on H3K9, H4K12 and H3K27 both in vitro and in vivo. It also induced cell cycle arrest at the G2/M phase in B16F10 and 4T1 cells. It caused significant Apoptosis and upregulated the expression of Caspase-3, caspase-7, cytochrome c and downregulated the expression of BCL2 in tumour tissue. In addition, the downregulation of CD44, EGFR and Ki-67 suggested the potential of compound 4e in reducing cell proliferation and metastasis in mice. Further, a marked decrease in the tumour volume was observed with no general toxicity in the major organs when treated with 4e in the 4T1-Luc xenograft mouse model. Therefore, compound 4e is a promising candidate selectively targeting HDAC3 with a significant antitumour activity that can be evaluated further in preclinical and clinical evaluation.

Keywords

Antitumour activity; Apoptosis; Benzoyl hydrazide; Pharmacokinetics; Selective HDAC3 inhibitor; Xenograft model.

Figures
Products